Get startedLog in
    Picture of ImmunoGen logo

    IMGN — ImmunoGen News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareSpeculativeLarge CapMomentum Trap
    All News

    Brief: FDA Grants Priority Review of ImmunoGen’s Supplemental Biologics License Application for ELAHERE® (mirvetuximab soravtansine-gynx) in Platinum-Resistant Ovarian Cancer

    Picture of ImmunoGen logoImmunoGen
    05/12/2023 11:34
    Dec 5 (Reuters) - ImmunoGen Inc  IMGN.O :
    * FDA GRANTS PRIORITY REVIEW OF IMMUNOGEN’S SUPPLEMENTAL
BIOLOGICS
LICENSE APPLICATION FOR ELAHERE® (MIRVETUXIMAB
SORAVTANSINE-GYNX) IN PLATINUM-RESISTANT OVARIAN CANCER
    * IMMUNOGEN INC: PRIORITY REVIEW GRANTED WITH PDUFA DATE OF
APRIL
5, 2024

Source text for Eikon:  ID:nBw4sxX6Ja 
Further company coverage:  IMGN.O 

 ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on ImmunoGen

    See all news